EDAP TMS S.A. Secures €36M EIB Credit Facility
Ticker: EDAP · Form: 6-K · Filed: Oct 20, 2025 · CIK: 1041934
| Field | Detail |
|---|---|
| Company | Edap Tms SA (EDAP) |
| Form Type | 6-K |
| Filed Date | Oct 20, 2025 |
| Risk Level | low |
| Pages | 9 |
| Reading Time | 11 min |
| Sentiment | bullish |
Sentiment: bullish
Topics: financing, debt, R&D, medical-technology
TL;DR
EDAP TMS just inked a €36M loan from EIB for R&D on their ultrasound tech. Big boost for prostate cancer treatments.
AI Summary
On October 17, 2025, EDAP TMS S.A. secured a €36.0 million credit facility agreement with the European Investment Bank (EIB). The company intends to utilize these funds to advance its research and development initiatives focused on robotic medical technology for treating conditions like prostate cancer using high-intensity focused ultrasound.
Why It Matters
This significant financing from the EIB will enable EDAP TMS to accelerate innovation in its robotic medical technology, potentially leading to new treatments for various medical conditions.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of a financing agreement and does not present immediate negative news.
Key Numbers
- €36.0 million — Credit Facility Amount (Funds to be used for research and development of robotic medical technology.)
Key Players & Entities
- EDAP TMS S.A. (company) — The company entering into the finance contract.
- European Investment Bank (company) — The lender providing the credit facility.
- €36.0 million (dollar_amount) — The total amount of the credit facility.
- October 17, 2025 (date) — The effective date of the finance contract.
FAQ
What is the primary purpose of the €36.0 million credit facility?
The company plans to use the proceeds to further its research and development projects relating to its robotic medical technology using high-intensity focused ultrasound.
Who is the lender for the new finance contract?
The finance contract is with the European Investment Bank (EIB).
On what date did EDAP TMS S.A. enter into the finance contract?
The company entered into the finance contract on October 17, 2025.
What specific medical conditions does EDAP TMS's technology aim to treat with this funding?
The company's robotic medical technology using high-intensity focused ultrasound is intended to treat various medical conditions such as prostate cancer.
What is the filing form type and date?
This is a Form 6-K filed on October 20, 2025.
Filing Stats: 2,776 words · 11 min read · ~9 pages · Grade level 20 · Accepted 2025-10-20 09:25:20
Filing Documents
- f6k_102025.htm (6-K) — 36KB
- exh_991.htm (EX-99.1) — 576KB
- exh_992.htm (EX-99.2) — 292KB
- exh_993.htm (EX-99.3) — 13KB
- edap_logo.jpg (GRAPHIC) — 7KB
- eib_logo.jpg (GRAPHIC) — 6KB
- schedule4.jpg (GRAPHIC) — 22KB
- 0001171843-25-006522.txt ( ) — 966KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. EDAP TMS S.A Date: October 20, 2025 By /s/ Ken Mobeck Ken Mobeck Chief Financial Officer